Role of animal studies in the design of clinical trials

Frontiers of Neurology and Neuroscience

Volumn 25, Issue , 2009, Pages 10-33

  Hall, Edward D ^a   Traystman, Richard J ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CLOMETHIAZOLE; COPPER ZINC SUPEROXIDE DISMUTASE; DISUFENTON SODIUM; ELIPRODIL; GABAERGIC RECEPTOR AFFECTING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIMODIPINE; PLACEBO; SCAVENGER; TIRILAZAD; TRAXOPRODIL;

ACUTE DISEASE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL WELFARE; BLOOD CLOT LYSIS; BRAIN CONTUSION; BRAIN EDEMA; BRAIN HEMORRHAGE; CELL THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MEGADOSE; DRUG SCREENING; DRUG TREATMENT FAILURE; EPILEPSY; ETHICS; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GENE OVEREXPRESSION; GENE THERAPY; HEART ARREST; HUMAN; KNOCKOUT GENE; KNOCKOUT MOUSE; METHODOLOGY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROSURGERY; NONHUMAN; OUTCOME ASSESSMENT; PARAMETER; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESUSCITATION; REVIEW; SAMPLE SIZE; SEX DIFFERENCE; SPINAL CORD INJURY; STROKE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SWINE; TRANSGENIC ANIMAL; TRANSGENIC RAT; TRAUMATIC BRAIN INJURY; ANIMAL; DISEASE MODEL;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES; RESEARCH DESIGN;

EID: 67649742960     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000209470     Document Type: Review

References (57)

1. Kofler J, Hattori K, Sawada M, DeVries C, Martin LJ, Hurn PD, Traystman R: Histopathological and behavioral characterization of a novel model of cardiac arrest and cardiopulmonary resuscitation in mice. J Neurosci Methods 2004;136:33-44.
2. Nishikawa T, Kirsch JR, Koehler RC, Miyabe M, Traystman RJ: Competitive N-methyl- D-aspartate receptor blockade reduces brain injury following transient focal ischemia in cats. Stroke 1994;25: 2258-2264.
3. Nishikawa T, Kirsch JR, Koehler RC, Miyabe M, Traystman RJ: Nitric oxide synthase inhibition reduces caudate injury following transient focal ischemia in cats. Stroke 1994;25:877-885.
4. Noppens RR, Kofler J, Hurn PD, Traystman RJ: Dose-dependent neuroprotection by 17β-estradiol after cardiac arrest and cardiopulmonary resuscitation. Crit Care Med 2005;33:15951-602.
5. Traystman RJ, Kirsch JR, Koehler RC: Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-1195.
6. Fournier AE, Strittmatter SM: Repulsive factors and axon regeneration in the CNS. Curr Opin Neurobiol 2001;11:89-94.
7. Gallo G, Letourneau PC: Regulation of growth cone actin filaments by guidance cues. J Neurobiol 2004;58:92-102.
8. McKerracher L: Spinal cord repair: strategies to promote axon regeneration. Neurobiol Dis 2001;8:11-18.
9. Ren JM, Finklestein SP: Growth factor treatment of stroke. Curr Drug Targets CNS Neurol Disord 2005;4:121-125.
10. Ginsberg MD, Busto R: Small animal models of global and focal cerebral ischemia; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease: Pathophysiology, Diagnosis and Management. Malden, Blackwell Science, 1998, pp 14-35.
11. Andrus PK, Fleck TJ, Oostveen JA, Hall ED: Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons. J Neurosci Res 1997;47:650-654.
12. Hall ED, Andrus PK, Oostveen JA, Althaus JS, Von Voigtlander PF: Neuroprotective effects of the dopamine D2/D3 agonist pramipixole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996;742:80-88.
13. Kagstrom E, Smith ML, Siesjo BK: Local cerebral blood flow in the recovery period following complete cerebral ischemia in the rat. J Cereb Blood Flow Metab 1983;3:170-182.
14. Smith ML, Bendek G, Dahlgren N, Rosen I, Wieloch T, Siesjo BK: Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. Acta Neurol Scan 1984;69: 385-401.
15. Pulsinelli WA , Brierley JB: A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979;10:267-272.
16. Pulsinelli WA , Brierley JB, Plum F: Temporal profile of neuronal damage in a model of transient fore-brain ischemia. Ann Neurol 1982;11:491-498.
17. Miller JD, Bullock R, Graham DI, Chen MH, Teasdale GM: Ischemic brain damage in a model of acute sub-dural hematoma. Neurosurg 1990;27:433-439.
18. Kline A, Dixon C: Contemporary in vivo models of brain trauma and a comparison of injury responses; in Miller L, Hayes R (eds): Head Trauma: Basic, Preclinical and Clinical Directions. New York, Wiley-Liss, 2001, pp 65-84.
19. Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW: Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma 2005;22:252-265.
20. Basso DM, Beattie MS, Bresnahan JC: Graded histo-logical and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 1996;139:244-256.
21. Scheff S W, Rabchevsky AG, Fugaccia I, Main JA, Lumpp JE Jr: Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma 2003;20:179-193.
22. Basso DM, Beattie MS, Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995;12:1-21.
23. Prins ML, Hovda DA: Developing experimental models to address traumatic brain injury in children. J Neurotrauma 2003;20:123-137.
24. Schneier AJ, Shields BJ, Hostetler SG, Xiang H, Smith GA: Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics 2006;118: 483-492.
25. Lynch JK, Hirtz DG, DeVeber G, Nelson KB: Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 2002;109:116-123.
26. Bittigau P, Sifringer M, Felderhoff-Mueser U, Hansen HH, Ikonomidou C: Neuropathological and biochemical features of traumatic injury in the developing brain. Neurotox Res 2003;5:475-490.
27. Duhaime AC: Large animal models of traumatic injury to the immature brain. Dev Neurosci 2006;28: 380-387.
28. Smith SL, Hall ED: Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. J Neurotrauma 1998; 15:707-719.
29. Smith SL, Andrus PK, Gleason DD, Hall ED: Infant rat model of the shaken baby syndrome: preliminary characterization and evidence for the role of free radicals in cortical hemorrhaging and progressive neuronal degeneration. J Neurotrauma 1998;15: 693-705.
30. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: Two decades of success and failure. NeuroRx 2004;1:36-45.
31. Labiche LA, Grotta JC: Clinical trials for cytopro-tection in stroke. NeuroRx 2004;1:46-70.
32. Murray GD, Teasdale GM, Schmitz H: Nimodipine in traumatic subarachnoid haemorrhage: A re-analysis of the HIT I and HIT II trials. Acta Neurochir (Wien) 1996;138:1163-1167.
33. Muizelaar JP, Kupiec J W, Rapp LA: PEG-SOD after head injury. J Neurosurg 1995;83:942.
34. Narayan RK, Michel ME, Ansell B: Clinical trials in head injury. J Neurotrauma 2002;19:503-557.
35. Hall ED, McCall JM, Means ED: Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 1994;28: 221-268.
36. Hall ED: Lazaroid: Mechanisms of Action and Implications for Disorders of the CNS. The Neuroscientist 1997;3:42-51.
37. Marshall LF, Maas AI, Marshall SB, Bricolo A, Fearnside M, Iannotti F, Klauber MR, Lagarrigue J, Lobato M, Persson L, Pickard J, Piek J, Servadei F, Wellis GN, Morris GF, Means ED, Musch B: A mul-ticenter trial on the efficacy of using tirilazad mesyl-ate in cases of head injury. J Neurosurg 1998;89: 519-525.
38. Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves WM: Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurys-mal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-228.
39. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon P W, Marshall LF, Nockels R P, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-1604.
40. Lanzino G, Kassell NF: Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999;90:1018-1024.
41. Lanzino G, Kassell NF, Dorsch NW, Pasqualin A, Brandt L, Schmiedek P, Truskowski LL, Alves WM: Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999;90: 1011-1017.
42. Green AR, Shuaib A: Therapeutic strategies for the treatment of stroke. Drug Discov Today 2006;11: 681-693.
43. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis S, Deiner HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski W: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
44. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis S, Diener HC, Ashwood T, Wasiewski W, Emeribe U: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-571.
45. Hall ED, Pazara KE, Linseman KL: Sex differences in postischemic neuronal necrosis in gerbils. J Cereb Blood Flow Metab 1991;11:292-298.
46. Roof RL, Hall ED: Estrogen-related gender difference in survival rate and cortical blood flow after impact-acceleration head injury in rats. J Neurotrauma 2000; 17:1155-1169.
47. Toung TJ, Traystman RJ, Hurn PD: Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 1998;29:1666-1670.
48. Hurn PD, Littleton-Kearney MT, Kirsch JR, Dharmarajan AM, Traystman RJ: Postischemic cerebral blood flow recovery in the female: Effect of 17β-estradiol. J Cereb Blood Flow Metab 1995;15: 666-672.
49. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M: Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 2001;142:969-973.
50. Wise PM, Dubal DB, Wilson ME, Rau S W, Liu Y: Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol 2001;22: 33-66.
51. Chan PH, Epstein CJ, Li Y: Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. J Neurotrauma 1995;12:815-824.
52. Tate CC, Garcia AJ, LaPlaca MC: Plasma fibronec-tin is neuroprotective following traumatic brain injury. Exp Neurol 2007;207:13-22.
53. Millecamps S, Gowing G, Corti O, Mallet J, Julien JP: Conditional NF-L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments. J Neurosci 2007;27:4947-4956.
54. O'Neal KR, Agah R: Conditional targeting: induc-ible deletion by Cre recombinase. Methods Mol Biol 2007;366:309-320.
55. Raab S, Beck H, Gaumann A. Impaired brain angio-genesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 2004; 91: 595-605.
56. Casper KB, Jones K, McCarthy KD. Characterization of astrocyte-specific conditional knockouts. Genesis 2007;45:292-299.
57. Licht AH, Raab S, Hofmann U, Breier G. Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. Dev Dyn 2004;229: 312-318.